NASDAQ:ICPTIntercept Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intercept Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $77.92 +1.54 (+2.02 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$76.87Now: $77.92▼$79.9750-Day Range$71.73MA: $81.35▼$92.0452-Week Range$47.57Now: $77.92▼$125.00Volume656,742 shsAverage Volume803,292 shsMarket Capitalization$2.57 billionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 14 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $144.88, Intercept Pharmaceuticals has a potential upside of 85.9% from its current price of $77.92.Amount of Analyst CoverageIntercept Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesIntercept Pharmaceuticals has received 1,017 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntercept Pharmaceuticals has received 619 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntercept Pharmaceuticals has received 62.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote “Outperform” if you believe ICPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,405,516.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Intercept Pharmaceuticals is held by insiders.Percentage Held by Institutions76.46% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($11.18) to ($7.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 49.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ICPT Previous Symbol CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone646-747-1000Debt Debt-to-Equity Ratio10.32 Current Ratio4.19 Quick Ratio4.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$252 million Price / Sales10.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.57 per share Price / Book49.63Profitability EPS (Most Recent Fiscal Year)($10.89) Net Income$-344,680,000.00 Net Margins-127.53% Return on Equity-430.51% Return on Assets-45.23%Miscellaneous Employees483 Outstanding Shares32,940,000Market Cap$2.57 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:ICPT Rates by TradingView Receive ICPT News and Ratings via Email Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions How has Intercept Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have increased by 0.4% and is now trading at $77.92. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Intercept Pharmaceuticals? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intercept Pharmaceuticals. When is Intercept Pharmaceuticals' next earnings date? Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intercept Pharmaceuticals. How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($2.86) EPS for the quarter, beating the Zacks' consensus estimate of ($2.94) by $0.08. The biopharmaceutical company had revenue of $72.60 million for the quarter, compared to analyst estimates of $69.67 million. Intercept Pharmaceuticals had a negative return on equity of 430.51% and a negative net margin of 127.53%. The company's quarterly revenue was up 39.1% on a year-over-year basis. During the same quarter last year, the business earned ($3.03) earnings per share. View Intercept Pharmaceuticals' earnings history. What price target have analysts set for ICPT? 18 Wall Street analysts have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $99.00 to $257.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $144.88 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View analysts' price targets for Intercept Pharmaceuticals. What are Wall Street analysts saying about Intercept Pharmaceuticals stock? Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock: 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019) 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019) Has Intercept Pharmaceuticals been receiving favorable news coverage? Media stories about ICPT stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutIntercept Pharmaceuticals. Are investors shorting Intercept Pharmaceuticals? Intercept Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,980,000 shares, an increase of 10.4% from the April 30th total of 4,510,000 shares. Based on an average trading volume of 579,900 shares, the days-to-cover ratio is presently 8.6 days. Currently, 15.8% of the company's shares are short sold. View Intercept Pharmaceuticals' Current Options Chain. Who are some of Intercept Pharmaceuticals' key competitors? Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Micron Technology (MU), Regeneron Pharmaceuticals (REGN) and Biogen (BIIB). Who are Intercept Pharmaceuticals' key executives? Intercept Pharmaceuticals' management team includes the following people: Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)Mr. Jerome B. Durso, Chief Operating Officer (Age 51)Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57) What is Intercept Pharmaceuticals' stock symbol? Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT." Who are Intercept Pharmaceuticals' major shareholders? Intercept Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sarissa Capital Management LP (3.51%), First Trust Advisors LP (1.69%), Two Sigma Advisers LP (1.64%), Geode Capital Management LLC (1.16%), Two Sigma Investments LP (1.01%) and EULAV Asset Management (0.46%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju. View institutional ownership trends for Intercept Pharmaceuticals. Which major investors are selling Intercept Pharmaceuticals stock? ICPT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Balyasny Asset Management LLC, Atom Investors LP, Rafferty Asset Management LLC, Pinnacle Associates Ltd., EULAV Asset Management, Parametric Portfolio Associates LLC, and Fisher Asset Management LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro, and Ryan T Sullivan. View insider buying and selling activity for Intercept Pharmaceuticals. Which major investors are buying Intercept Pharmaceuticals stock? ICPT stock was bought by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Two Sigma Advisers LP, Advisor Group Holdings Inc., Quantitative Investment Management LLC, Two Sigma Investments LP, Engineers Gate Manager LP, Geode Capital Management LLC, and Pictet Asset Management Ltd.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Luca Benatti, and Srinivas Akkaraju. View insider buying and selling activity for Intercept Pharmaceuticals. How do I buy shares of Intercept Pharmaceuticals? Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Intercept Pharmaceuticals' stock price today? One share of ICPT stock can currently be purchased for approximately $77.92. How big of a company is Intercept Pharmaceuticals? Intercept Pharmaceuticals has a market capitalization of $2.57 billion and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe. What is Intercept Pharmaceuticals' official website? The official website for Intercept Pharmaceuticals is www.interceptpharma.com. How can I contact Intercept Pharmaceuticals? Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected] This page was last updated on 6/7/2020 by MarketBeat.com Staff
